| Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism … NJ Hewitt, MJ Gómez Lechón, JB Houston, D Hallifax, HS Brown, ... Drug metabolism reviews 39 (1), 159-234, 2007 | 867 | 2007 |
| Managing the challenge of chemically reactive metabolites in drug development BK Park, A Boobis, S Clarke, CEP Goldring, D Jones, JG Kenna, ... Nature Reviews Drug Discovery 10 (4), 292-306, 2011 | 503 | 2011 |
| In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans S Dawson, S Stahl, N Paul, J Barber, JG Kenna Drug Metabolism and Disposition 40 (1), 130-138, 2012 | 346 | 2012 |
| The immunologic and metabolic basis of drug hypersensitivities LR Pohl, H Satoh, DD Christ, JG Kenna Annual review of pharmacology and toxicology 28 (1), 367-387, 1988 | 281 | 1988 |
| Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group … JG Kenna, H Satoh, DD Christ, LR Pohl Journal of Pharmacology and Experimental Therapeutics 245 (3), 1103-1109, 1988 | 280 | 1988 |
| The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human TB Andersson, KP Kanebratt, JG Kenna Expert opinion on drug metabolism & toxicology 8 (7), 909-920, 2012 | 271 | 2012 |
| Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity GP Aithal, L Ramsay, AK Daly, N Sonchit, JBS Leathart, G Alexander, ... Hepatology 39 (5), 1430-1440, 2004 | 264 | 2004 |
| The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys … JM Hourihan, JG Kenna, JD Hayes Antioxidants & redox signaling 19 (5), 465-481, 2013 | 247 | 2013 |
| In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs RA Thompson, EM Isin, Y Li, L Weidolf, K Page, I Wilson, S Swallow, ... Chemical research in toxicology 25 (8), 1616-1632, 2012 | 238 | 2012 |
| Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. E Eliasson, JG Kenna Molecular pharmacology 50 (3), 573-582, 1996 | 207 | 1996 |
| Methods for reducing non-specific antibody binding in enzyme-linked immunosorbent assays JG Kenna, GN Major, RS Williams Journal of immunological methods 85 (2), 409-419, 1985 | 203 | 1985 |
| Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. H Satoh, BM Martin, AH Schulick, DD Christ, JG Kenna, LR Pohl Proceedings of the National Academy of Sciences 86 (1), 322-326, 1989 | 200 | 1989 |
| The organ toxicity of inhaled anesthetics JG Kenna, RM Jones Anesthesia & Analgesia 81 (6S), 51S-66S, 1995 | 188 | 1995 |
| Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. DD Christ, JG Kenna, W Kammerer, H Satoh, LR Pohl Anesthesiology 69 (6), 833-838, 1988 | 132 | 1988 |
| Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis GJ Kenna, J Neuberger, R Williams Hepatology 8 (6), 1635-1641, 1988 | 129 | 1988 |
| Neoantigens associated with halothane hepatitis LR Pohl, JG Kenna, H Satoh, D Christ, JL Martin Drug metabolism reviews 20 (2-4), 203-217, 1989 | 124 | 1989 |
| Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. DD Christ, H Satoh, JG Kenna, LR Pohl Drug Metabolism and Disposition 16 (1), 135-140, 1988 | 121 | 1988 |
| Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated … JG Kenna, J Neuberger, R Williams Journal of Pharmacology and Experimental Therapeutics 242 (2), 733-740, 1987 | 119 | 1987 |
| Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development RA Thompson, EM Isin, Y Li, R Weaver, L Weidolf, I Wilson, A Claesson, ... Chemico-biological interactions 192 (1-2), 65-71, 2011 | 101 | 2011 |
| Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes H Garside, KF Marcoe, J Chesnut-Speelman, AJ Foster, D Muthas, ... Toxicology in Vitro 28 (2), 171-181, 2014 | 98 | 2014 |